PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

Date of mailing (day/month/year)
28 January 1999 (28.01.99)

Applicant's or agent's file reference 339217/17609

International application No. PCT/IB98/01091

International filing date (day/month/year) 16 July 1998 (16.07.98)

nonth/year) Priority date (day/month/year) 16 July 1997 (16.07.97

From the INTERNATIONAL BUREAU

MARTIN, Jean-Jacques Cabinet Regimbeau 26, avenue Kléber

F-75116 Pariş

FRANCE

IMPORTANT NOTICE

Applicant

INSTITUT PASTEUR et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:

AU,BR,CA,CN,EP,IL,JP,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AL,AM,AP,AT,AZ,BA,BB,BG,BY,CH,CU,CZ,DE,DK,EA,EE,ES,FI,GB,GE,GH,GM,HR,HU,ID,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,

SL,TJ,TM,TR,TT,UA,UG,UZ,VN,YU,ZW
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 28 January 1999 (28.01.99) under No. WO 99/04005

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

J. Zahra

Telephone No. (41-22) 338.83.38

Facsimile No. (41-22) 740.14.35

PATENT COOPERATION TREATY

	From the INTERNATIONAL BUREAU		
PCT	To:		
NOTIFICATION OF ELECTION (PCT Rule 61.2)	United States Patent and Trademark Office (Box PCT) Crystal Plaza 2 Washington, DC 20231 ÉTATS-UNIS D'AMÉRIQUE		
Date of mailing (day/month/year)			
09 March 1999 (09.03.99)	in its capacity as elected Office		
International application No. PCT/IB98/01091	Applicant's or agent's file reference 339217/17609		
International filing date (day/month/year)	Priority date (day/month/year)		
16 July 1998 (16.07.98)	16 July 1997 (16.07.97)		
Applicant			
GICQUEL, Brigitte et al			
1. The designated Office is hereby notified of its election mad X in the demand filed with the International Preliminary 08 February 15	y Examining Authority on: 999 (08.02.99) national Bureau on:		
The International Bureau of WIPO	Authorized officer		
34, chemin des Colombettes 1211 Geneva 20, Switzerland	Lazar Joseph Panakal		
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38		

2515847



INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rul s 43 and 44)

Applicant's or agent's file reference	(1	ee Notification of Transr	mittal of International Search Report well as, where applicable, item 5 below.
339217/17609	ACTION		
International application No.	International filing date (day/	<i>month/year)</i> (Earl	iest) Priority Date (day/month/year)
PCT/IB 98/01091	16/07/1998		16/07/1997
Applicant			
INSTITUT PASTEUR et al.			
This International Search Report has be according to Article 18. A copy is being	een prepared by this Internationa transmitted to the International B	Searching Authority an ureau	d is transmitted to the applicant
This International Search Report consis	ts of a total of4 ppy of each prior art document cit	_ sheets. ed in this report.	
Certain claims were found u	nsearchable (see Box I).	·	
2. Unity of invention is lacking	(see Box II).		
3. X The international application of international search was carried.	ontains disclosure of a nucleotic ed out on the basis of the sequen	le and/or amino acid s ce listing	equence listing and the
file	ed with the international applicati	on.	
X fu	rnished by the applicant separate	•	• • • • • • • • • • • • • • • • • • • •
	but not accompanied by a matter going beyond the c	statement to the effect lisclosure in the internat	that it did not include ional application as filed.
☐ Tr	anscribed by this Authority		
4. With regard to the title, χ the	e text is approved as submitted b	y the applicant.	
the	e text has been established by th	is Authority to read as fo	ollows:
	,		
5. With regard to the abstract,			
	e text is approved as submitted b		
Во	e text has been established, acco ix III. The applicant may, within o arch Report, submit comments to	ne month from the date :	y this Authority as it appears in of mailing of this International
6. The figure of the drawings to be put	olished with the abstract is:		
_	suggested by the applicant.		χ None of the figures.
be	cause the applicant failed to sugg	jest a figure.	-
be	cause this figure better character	izes the invention.	Ì
		•	

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/31, C07K 14/35, C12N 15/62, C07K 19/00, C12N 15/74, G01N 33/53, C12N 1/21, C07K 16/12, A61K 39/04, C12Q 1/68 // (C12N 1/21, C12R 1:32, 1:19, 1:34, 1:38, 1:42)

(11) International Publication Number:

WO 99/04005

(43) International Publication Date:

28 January 1999 (28.01.99)

(21) International Application Number:

PCT/IB98/01091

A1

(22) International Filing Date:

16 July 1998 (16.07.98)

(30) Priority Data:

60/052,631

16 July 1997 (16.07.97)

US

(71) Applicants (for all designated States except US): INSTITUT PASTEUR [FR/FR]; 28, rue du Docteur Roux, F-75015 Paris (FR). STATENS SERUM INSTITUT [DK/DK]; Artillerivej 5, DK-2300 Copenhagen 5 (DK).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): GICQUEL, Brigitte [FR/FR]; 8, rue Daguerre, F-75014 Paris (FR). BERTHET, François-Xavier [FR/FR]; 86, rue Olivier de Serres, F-75015 Paris (FR). ANDERSEN, Peter [DK/DK]; Lystrupvej 7, DK-2700 Brønshøj (DK). RASMUSSEN, Peter, Birk [DK/DK]; Rudolph Bergsgade 5, DK-2100 København Ø (DK).
- (74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: A POLYNUCLEOTIDE FUNCTIONALLY CODING FOR THE LHP PROTEIN FROM MYCOBACTERIUM TUBERCU-LOSIS, ITS BIOLOGICALLY ACTIVE DERIVATIVE FRAGMENTS, AS WELL AS METHODS USING THE SAME

(57) Abstract

The present invention is directed to a polynucleotide carrying a n open reading frame coding for an antigenic polypeptide from Mycobacterium tuberculosis, named lhp, which is placed under the control of its own regulation signals which are functional in mycobacteria, specially in mycobacteria belonging to the Mycobacterium tuberculosis complex and also in fast growing mycobacteria such as Mycobacterium smegmatis. The invention is also directed to the polypeptide LHP encoded by lhp and most preferably to suitable antigenic portions of LHP as well as to oligomeric polypeptides containing more than one unit of LHP or an antigenic portion of LHP. The invention concerns also immunogenic and vaccine compositions containing a polypeptide or an oligomeric polypeptide such as defined above, as well as antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. In another embodiment, the present invention is directed to a polynucleotide carrying the natural regulation signals of lhp which is useful in order to express heterologous proteins in mycobacteria. Finally, the present invention is directed to oligonucleotides comprising at least 12 consecutive nucleotides from the regulation sequence of lhp which are useful as reagents for detecting the presence of Mycobacterium tubercolosis in a biological sample.




FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	ΙE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	ΙL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	. LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

IONAL SEARCH REPORT INTER



A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/31 C071 C07K14/35 C07K19/00 C12N15/74 C12N15/62 G01N33/53 C12N1/21 C07K16/12 A61K39/04 C12Q1/68, //(C12N1/21,C12R1:32,1:19,1:34,1:38,1:42) According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N C07K G01N A61K C12Q IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electromo data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category 6 X WO 97 09428 A (CORIXA CORP; REED; SKEIKY; 1-7. DILLON; CAMPOS-NETO; HOUGHTON; VEDVICK 9-13. 15-53 (US)) 13 March 1997 cited in the application see abstract see page 17, line 4-22 see page 18, line 12-20 see page 23, line 7-24 see page 37, line 12 - page 42 Seq.ID:46, 47, 88, 93-98, 112-119 see page 83 - page 84 see page 124 see page 128 - page 131 see page 143 - page 150 see page 158 - page 163; claims Patent family members are listed in annex. Further documents are listed in the continuation of box C. Х Special categories of cited documents : "I later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another document of particular relevance: the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the *O* document referring to an oral disclosure, use, exhibition or document is combined with one or more other such documents, such combination being obvious to a person skilled Other means document published prior to the international filing date but "&" document member of the same patent family later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report **28** 40. 98 22 October 1998 Name and mailing address of the ISA **Authorized officer** European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,

Form PCT/ISA/210 (second sheet) (July 1992)

Fax: (+31-70) 340-3016

1

Macchia, G

PCT/IB 98/01091

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	
	depropried, of the relevant passages	Relevant to claim No.
X	WO 97 09429 A (CORIXA CORP; REED; SKEIKY; DILLON; CAMPOS-NETO; HOUGHTON; VEDVICK (US)) 13 March 1997 cited in the application	1-7, 9-13, 15-53
A	see abstract see page 14, line 23 - page 15, line 2 see page 35, line 21 - page 36, line 13 see page 39, line 22 - page 42 Seq.ID:46, 47, 89, 107-114 see page 88 - page 89 see page 135 - page 136 see page 157 - page 164 see page 173 - page 181; claims see figures 3-5	54,55
X	WO 96 25519 A (PATHOGENESIS CORPORATION (US); STOVER C.K. (US); MAHAIRAS G.G. (US)) 22 August 1996 see page 1, line 28 - page 4, line 31 see page 11, line 1-14; figures 1,4 see page 37, line 13 - page 38, line 8 see page 41 - page 44; claims	1-6, 9-12,15, 34-43
P,X	Database EMBL R55U027, Entry AF004671 Accession number AF004671 29 June 1998 99% identity with Seq.ID:1 XP002081660 see the whole document	1,2,4,5, 17,20
P,X	WO 98 16645 A (CORIXA CORP; REED; SKEIKY; DILLON; CAMPOS-NETO; HOUGHTON; VEDVICK (US)) 23 April 1998 see abstract see page 21, line 10 - page 28, line 17 Seq.ID:46, 47, 89, 107-114, 147, 148, 208, 209	1-6,9, 16,17, 20,22, 25,30-43
	see page 90 see page 141 - page 147 see page 162 - page 166 see page 218 - page 226 see page 227 - page 236; claims -/	

		PC1/1B 98/01091
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category 3	Charlett of Document, with indication, where appropriate, or the relevant bassages	, teastant to statin to.
P,X	WO 98 16646 A (CORIXA CORP; REED; SKEIKY; DILLON; CAMPOS-NETO; HOUGHTON; VEDVICK (US)) 23 April 1998	1-6,9, 10,12, 16,17, 20-22, 24, 26-29, 31,33
	see page 23, line 27 - page 29, line 7 see page 41, line 12 - page 49, line 3 Seq.ID:46, 47, 88, 93-98, 112-119, 152, 153, 213, 214 see page 88 - page 89 see page 117 - page 118 see page 121 - page 123 see page 135 - page 141 see page 154 - page 157 see page 204 - page 211 see page 212 - page 217; claims	
A	EP 0 400 973 A (AJINOMOTO KK ;YAMADA TAKESHI (JP)) 5 December 1990 see column 5, line 37-41 see column 6, line 6-11	10-12,15
A	TAM J.P.: "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, August 1988, pages 5409-5413, XP002070407 cited in the application see the whole document	18,19,23
A	SATHISH M. ET AL.: "Identification and characterization of antigenic determinants of Mycobacterium leprae that react with antibodies in sera of leprosy patients" INFECTION AND IMMUNITY, vol. 58, no. 5, May 1990, pages 1327-1336, XP002081659 cited in the application	

1



stemational Application No

Information on patent family members

PC	T	/ I	В	98	3/	0	1	0	9	1
	• •	•	_		-,	•	_	•	_	-

Patent document cited in search report			Publication date			
WO 9709428	Α	13-03-1997		7158696 A 0851927 A 980883 A 325373 A	27-03-1997 08-07-1998 27-04-1998	
WO 9709429	Α	13-03-1997	AU	7158796 A 0850305 A	20-07-1998 27-03-1997 01-07-1998	
W0 9625519	Α	22-08-1996		5700683 A 4979696 A	23-12-1997 04-09-1996	
WO 9816645	Α	23-04-1998	AU	4750597 A	11-05-1998	: ;
WO 9816646	Α	23-04-1998	AU	4814497 A	11-05-1998	;
EP 0400973	A	05-12-1990	DE 6	9027956 D 9027956 T 3072888 A	05-09-1996 06-03-1997 28-03-1991	:

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To

MARTIN, Jean-Jacques Cabinet REGIMBEAU 26, avenue Kléber 75116 Paris FRANCE



16/07/1998

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing (day/month/year)

0 8. 10. 99

IMPORTANT NOTIFICATION

Applicant's or agent's file reference 339217/17609

International application No.

PCT/IB98/01091

International filing date (day/month/year)

Priority date (day/month/year) 16/07/1997

Applicant

INSTITUT PASTEUR et al.

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

Authorized officer

Schou, S

)) D

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Tel.+49 89 2399-8062





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		FOR FURTHER AC	See Not	ification of Transmittal of International ary Examination Report (Form PCT/IPEA/416)	;)
339217/1					
	al application No.	International filing date (d	day/month/year)	Priority date (day/month/year) 16/07/1997	
PCT/IB98		16/07/1998		16/0//199/	
International C12N15/		(IPC) or national classification and IPC	<i>;</i>		
Applicant				Total Control	
INSTITU	T PASTEUR et al				
		nary examination report has been applicant according to Article 36.	prepared by this l	nternational Preliminary Examining Author	ority
2. This f	REPORT consists o	f a total of 5 sheets, including this	cover sheet.		
b (s	een amended and	are the basis for this report and/or Section 607 of the Administrative	sheets containing	tion, claims and/or drawings which have rectifications made before this Authority r the PCT).	; f
3. This r	eport contains indic	ations relating to the following iten	ns:		
П	☐ Priority				
III		hment of opinion with regard to no	velty, inventive st	ep and industrial applicability	
V	☑ Lack of unity☑ Reasoned st	atement under Article 35(2) with re	egard to novelty, in	nventive step or industrial applicability;	
VI	Citations and	explanations suporting such state	ament	•	
VII		cts in the international application			
VIII		rvations on the international applic	cation		
Data of out	emission of the deman		Date of completion	of this report	
08/02/19		1	Date of completion	8. 10. 99	
	mailing address of the examining authority:	international	Authorized officer	(LachSOES)	Microso
	European Patent Of D-80298 Munich	fice	Grosskopf, R	·	
الا		Tx: 523656 epmu d		150 2200 8714	- Elizabeth

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IB98/01091

l.	Bas	is	of	th	re	DO	rt

1.	resp	This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):							
	Description, pages:								
	1-5	e	as originally filed						
	Cla	ims, No.:							
	1-55		as originally filed —						
	Dra	wings, sheets:							
	1/13	3-13/13	as originally filed						
2.	The	amendments have	e resulted in the cancellation of:						
		the description,	pages:						
		the claims,	Nos.:						
		the drawings,	sheets:						
3.			en established as if (some of) the amendments had not been made, since they have been beyond the disclosure as filed (Rule 70.2(c)):						
4.	Ado	litional observation	s, if necessary:						
111.	. Noi	n-establishment o	f opinion with regard to novelty, inventive step and industrial applicability						
Th or	ne qu to be	estions whether the industrially applic	e claimed invention appears to be novel, to involve an inventive step (to be non-obvious), able have not been examined in respect of:						
		the entire internat	ional application.						
	☒	claims Nos. 1-55.							
be	caus	se:							

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IB98/01091

		the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (<i>specify</i>):
	×	the description, claims or drawings (indicate particular elements below) or said claims Nos. 1-55 are so unclear that no meaningful opinion could be formed (specify):
		see separate sheet
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
		no international search report has been established for the said claims Nos
IV.	. Lac	k of unity of invention
1.	In re	esponse to the invitation to restrict or pay additional fees the applicant has:
		restricted the claims.
		paid additional fees.
		paid additional fees under protest.
		neither restricted nor paid additional fees.
2.	Ø	This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
		complied with.
	×	not complied with for the following reasons:
		see separate sheet
4.		sequently, the following parts of the international application were the subject of international preliminary mination in establishing this report:
	⊠	all parts.
		the parts relating to claims Nos

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

International application No. PCT/IB98/01091

- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes:

Claims

No:

Claims 1

Inventive step (IS)

Yes:

Claims

Claims

No:

Claims 1-55

Industrial applicability (IA)

Yes:

Claims 1-55

No:

2. Citations and explanations

see separate sheet

Ad item V:

The basis for all claimed subject-matter appears to be the sequence of Claim 1(a). Said sequence, however, is (with three or four exceptions) identical to a sequence disclosed in D1 (WO 97/09248; see e.g. SEQ ID NO: 112). Since the sequence (or subsequences thereof or the corresponding polypeptides) of D1 has been used for the same purposes, at present, not **any** subject-matter is recognisable which might constitute the basis for an inventive claim.

Ad item III and IV:

Moreover, the present set of claims is objectionable for so many other reasons that it is impossible to carry out a meaningful or even complete examination with regard to each and every embodiment claimed.

Thus, this opinion has to be limited to some of the (basic) objections. A detailed final examination of any subject-matter (i.e. in the final opinion) could only be carried out if at least these basic objections were removed.

First, the set of claims comprises a myriad of different entities, said entities not being linked by a common structural feature and thus not being linked by a common inventive concept (as one example see e.g. items (e) and (g) of Claim 1). In order to comply with the requirements for a unitary concept, only the claiming of those entities were acceptable which share such a common structural **special** feature, i.e. a feature which is common to all entities claimed **and** which is suitable to distinguish the claimed entities from the prior art (e.g. D1).

It goes without saying that in view of the identity of the sequences disclosed in D1 and the present application, such a feature is not even recognisable for **two** different entities (let alone for more).

As a consequence, at best **one** independently claimed entity could be accepted (but not different alternatives within one claim).

Any broadening (see e.g. Claim 1 (e) to (g)) must not only result in an objection for lack of clarity (since the scope of said subparts are totally unlimited) but, especially in view of the prior art, in further novelty objections.